Emcure Pharmaceuticals delivered a strong Q1FY27. Revenue surged 22.8% YoY to ₹2,580.4 Cr, while Net Profit jumped 36.2% YoY to ₹292.5 Cr.

The International business was a key driver, growing 34.2% YoY and contributing 58% of total revenue with robust performance across Europe, RoW, and Canada.

Domestic business also saw a 10.2% growth, boosted by CNS, women's health, and cardio-metabolics segments, along with an increasing chronic segment share.

Strategic leadership changes include Mr. Satish Mehta taking over as Chairman, MD & CEO, and Mr. Samit Mehta appointed COO of Emcure and CEO of Gennova Biopharmaceuticals (now a wholly-owned subsidiary), strengthening leadership and biologics capabilities.

Recent highlights include new product approvals and launches in international markets and a licensing agreement with MSD for a PrEP candidate.

EBITDA margin improved by 50 bps to 19.7%, and PAT margin rose 110 bps to 11.3%, reflecting productivity gains.

Management anticipates continued growth, especially in the domestic market, driven by a strengthened team and portfolio, and sustained performance across its diversified international platform.